laquinimod

 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

ABR 215062

Broader (1)

Quinolones

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis
The phase III placebo-controlled BRAVO study assessed laquinimod effects in patients with relapsing-remitting MS (RRMS), and… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2013
2013
Laquinimod prevents inflammation-induced synaptic alterations occurring in experimental autoimmune encephalomyelitis.
BACKGROUND There are two generally accepted strategies for treating multiple sclerosis (MS), preventing central nervous system… (More)
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Placebo-controlled trial of oral laquinimod for multiple sclerosis.
BACKGROUND Two proof-of-concept clinical trials have provided evidence that laquinimod reduces disease activity in patients with… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • table 3
Is this relevant?
2012
2012
Kinetics of proinflammatory monocytes in a model of multiple sclerosis and its perturbation by laquinimod.
Proinflammatory circulating monocytes have important roles in the pathology of multiple sclerosis (MS) and its animal model… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Laquinimod is a promising, orally available compound that has been successfully evaluated in placebo-controlled phase II/III… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Insight into the mechanism of laquinimod action
Laquinimod is a small, novel, orally active, well-tolerated molecule that significantly reduced gadolinium-enhancing lesions in… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
BACKGROUND A 24-week phase II trial has shown that 0.3 mg of laquinimod given daily to patients with relapsing-remitting multiple… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
Highly Cited
2005
Highly Cited
2005
Treatment with laquinimod reduces development of active MRI lesions in relapsing MS.
BACKGROUND Laquinimod is a novel immunomodulatory substance developed as an orally available disease modifying treatment in… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats
The new orally active drug laquinimod (ABR-215062) was evaluated in experimental autoimmune encephalomyelitis (EAE) in the Lewis… (More)
Is this relevant?
Highly Cited
2002
Highly Cited
2002
The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis
A new orally active drug, laquinimod (ABR-215062), was shown to completely inhibit the development of murine acute experimental… (More)
Is this relevant?